Back to discover
Drug

Interferon-beta

Regulatory activity · MHRA
Emerging researchLate-stage development

Also known as Fibroblast interferon, interferon beta natural, Interferon beta.

RxNorm4381
1
Research papers
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Tolerance-Induction With Dendritic Cells Treated With Vitamin-D3 and Loaded With Myelin Peptides, in Multiple Sclerosis Patients (TOLERVIT-MS)

Clinical trial2023-12-01Primary completion · ClinicalTrials.gov

Anti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized Trial

Clinical trial2022-12-30Completed · ClinicalTrials.gov

A Phase II, Multicenter, Randomized, Double Blind, Placebo Controlled, Safety, Tolerability and Efficacy Study of Add-on Cladribine Tablet Therapy With Interferon-beta (IFN-β) Treatment in Multiple Sclerosis Subjects With Active Disease

Clinical trial2020-10-12Results posted · ClinicalTrials.gov

Open-label, Randomized, 2-arm, Active Comparator Study to Evaluate Safety and Tolerability in Patients With Relapsing Multiple Sclerosis Transitioning From Standard-of-care Subcutaneous Interferon Therapy to Peginterferon Beta-1a (BIIB017)

Clinical trial2018-03-01Withdrawn · ClinicalTrials.gov

A Phase I/II Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of FP-1201 (Recombinant Human Interferon Beta) in the Treatment of Patients With Acute Lung Injury and Acute Respiratory Distress Syndrome.

Clinical trial2015-05-27Results posted · ClinicalTrials.gov

Drug Safety Update: Interferon-beta: risk of thrombotic microangiopathy and risk of nephrotic syndrome

Regulatory2014-12-11MHRA

The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study.

Research2013-12-23The Lancet. Respiratory medicine

A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis Who Are Treated With Interferon-beta

Clinical trial2013-04-01Terminated · ClinicalTrials.gov

A Monocentric, Randomized, Controlled Trial to Test the Efficacy of Interferon-beta in the Treatment of Disseminated Encephalomyelitis (ED)-Associated and Primary Intermediate Uveitis in Comparison to Standard Treatment (TEAM)

Clinical trial2012-01-01Completed · ClinicalTrials.gov

Randomized Study of Beta Interferon and Thalidomide in Patients With Adrenoleukodystrophy

Clinical trial2000-11-01Completed · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Interferon-beta
Aliases & brands
Fibroblast interferoninterferon beta naturalInterferon beta
RxNorm CUI
4381
Regulatory jurisdictions
mhra

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Authorities
MHRA
Total events
1
mhraMedicines and Healthcare products Regulatory Agency· 1 event
2014-12-11Safety communicationSafety
Drug Safety Update: Interferon-beta: risk of thrombotic microangiopathy and risk of nephrotic syndrome
Evidence ↗

Contains public sector information from the Medicines and Healthcare products Regulatory Agency (MHRA) licensed under the Open Government Licence (OGL v3).

Clinical trials

8 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
8
registered trials across all phases
LATEST COMPLETION 2022
5
Late-stage (III+)
5
Completed
3
Discontinued
PHASE DISTRIBUTIONn = 8
Phase 11Phase 1 / 21Phase 21Phase 33Phase 41Phase N / A1

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Open-label, Randomized, 2-arm, Active Comparator Study to Evaluate Safety and Tolerability in Patients With Relapsing Multiple Sclerosis Transitioning From Standard-of-care Subcutaneous Interferon Therapy to Peginterferon Beta-1a (BIIB017)

WithdrawnPH IVBiogen2018

Anti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized Trial

CompletedPH IIIKey trialPopulation Health Research Instituten=6,6672022

A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis Who Are Treated With Interferon-beta

TerminatedPH IIISanofin=5342013

A Monocentric, Randomized, Controlled Trial to Test the Efficacy of Interferon-beta in the Treatment of Disseminated Encephalomyelitis (ED)-Associated and Primary Intermediate Uveitis in Comparison to Standard Treatment (TEAM)

CompletedPH IIIHeidelberg Universityn=192012

Recent completions

Trials that read out recently, adding to the completed evidence base.

Anti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized Trial

CompletedPH IIIKey trialPopulation Health Research Instituten=6,6672022

A Phase II, Multicenter, Randomized, Double Blind, Placebo Controlled, Safety, Tolerability and Efficacy Study of Add-on Cladribine Tablet Therapy With Interferon-beta (IFN-β) Treatment in Multiple Sclerosis Subjects With Active Disease

CompletedPH IIEMD Serono Research & Development Institute, Inc.n=1722012

A Monocentric, Randomized, Controlled Trial to Test the Efficacy of Interferon-beta in the Treatment of Disseminated Encephalomyelitis (ED)-Associated and Primary Intermediate Uveitis in Comparison to Standard Treatment (TEAM)

CompletedPH IIIHeidelberg Universityn=192012

A Phase I/II Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of FP-1201 (Recombinant Human Interferon Beta) in the Treatment of Patients With Acute Lung Injury and Acute Respiratory Distress Syndrome.

CompletedPH I/IIFaron Pharmaceuticals Ltdn=372011

Randomized Study of Beta Interferon and Thalidomide in Patients With Adrenoleukodystrophy

CompletedN/AFDA Office of Orphan Products Developmentn=602000

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Journals, researchers & institutions
Top journals
  • The Lancet. Respiratory medicine1
Leading researchers
  • Beale R1
  • Beatty M1
  • Bellingan G1
  • Binning A1
  • Cooper J1
  • Davidson A1
  • Howell DC1
  • Jalkanen J1
Leading institutions
free-text, unnormalised
  • Bristol Royal Infirmary1
  • Centre for Cardiovascular Genetics1
  • MediCity Research Laboratory1
  • Royal Infirmary Edinburgh1
  • St Mary's Imperial College Hospital1
  • St Thomas's Hospital1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.